Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his department has taken to make the drug Enhertu available for people with secondary breast cancer in England, following the increase in NICE’s cost effectiveness thresholds in April 2026.

Following the increase in the National Institute for Health and Care Excellence’s (NICE) cost-effectiveness thresholds in April 2026, NICE, NHS England, and the manufacturers have resumed discussions to explore whether a commercial offer can be agreed that would make Enhertu cost-effective for HER2-low metastatic or unresectable breast cancer.

NICE previously published guidance in July 2024 and did not recommend Enhertu for this indication because the cost-effectiveness estimates were above the acceptable range for National Health Service resources.

Those discussions are ongoing. NICE and NHS England remain committed to securing access to effective treatments where they represent value for NHS patients.